Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer

NCT00564720 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

140

Enrollment

OTHER

Sponsor class

Stopped Due to poor accrual of the study

Conditions

Pancreatic Cancer

Interventions

DRUG: Gemcitabine
DRUG: Gemcitabine
DRUG: Erlotinib
DRUG: Oxaliplatin

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]